Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Weighted Average) (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $1250.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) fell 100.0% year-over-year to $1250.0, compared with a TTM value of $1250.0 through Sep 2025, down 100.0%, and an annual FY2024 reading of $70.9 million, changed 0.46% over the prior year.
  • Shares Outstanding (Weighted Average) was $1250.0 for Q3 2025 at Ovid Therapeutics, roughly flat from $1250.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $70.9 million in Q4 2024 and bottomed at $1250.0 in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $58.7 million, with a median of $70.4 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 21.38% in 2021, then tumbled 100.0% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $67.5 million in 2021, then grew by 4.36% to $70.4 million in 2022, then rose by 0.22% to $70.6 million in 2023, then grew by 0.46% to $70.9 million in 2024, then plummeted by 100.0% to $1250.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for OVID at $1250.0 in Q3 2025, $1250.0 in Q2 2025, and $1250.0 in Q1 2025.